New hope for advanced liver cancer: first human trial of ABSK-011 begins

NCT ID NCT04906434

Recruiting now Disease control Sponsor: Abbisko Therapeutics Co, Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug called ABSK-011 in about 200 people with advanced solid tumors, especially liver cancer that has not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. Participants will receive the drug and be closely monitored for side effects and tumor response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma liver cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED LIVER CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Beijing Tsinghua Changgung Hospital
RECRUITING

Beijing, Beijing Municipality, China
Chongqing Cancer Hospital
RECRUITING

Chongqing, Chongqing Municipality, China
First Affiliated Hospital of Henan University of Science and Technology
COMPLETED

Luoyang, Henan, China
Fujian Provincial Cancer Hospital
COMPLETED

Fuzhou, Fujian, China
General Hospital of Ningxia Medical University
COMPLETED

Yinchuan, Ningxia, China
Guangxi Zhuang Autonomous Region People's Hospital
COMPLETED

Nanning, Guangxi, China
Harbin Medical University Cancer Hospital
RECRUITING

Haerbin, Heilongjiang, China
Henan Cancer Hospital
COMPLETED

Zhengzhou, Henan, China
Hubei Cancer Hospital
COMPLETED

Wuhan, Hubei, China
Hunan Cancer Hospital
COMPLETED

Changsha, Hunan, China
Hunan Provincial People's Hospital
WITHDRAWN

Changsha, Hunan, China
Icahn School of Medicine at Mount Sinai
RECRUITING

New York, New York, 10029, United States

Contact Email: •••••@•••••
Jinan Central Hospital
COMPLETED

Jinan, Shandong, China
Linyi Cancer Hospital
COMPLETED

Linyi, Shandong, China
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

Contact Email: •••••@•••••
Mayo Clinic
RECRUITING

Phoenix, Arizona, 85054, United States
Mayo Clinic
RECRUITING

Jacksonville, Florida, 32224, United States
Mayo Clinic
RECRUITING

Rochester, Minnesota, 55905, United States
Mianyang Central Hospital
RECRUITING

Mianyang, Sichuan, China
Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States
Nation Taiwan University Hospital
COMPLETED

Taipei, Taiwan
National Cheng Kung University Hospitals
COMPLETED

Tainan, Taiwan
Ningbo Huamei Hospital, University of Chinese Academy of Sciences
WITHDRAWN

Ningbo, Zhejiang, China
Shengjing Hospital of China medical university
COMPLETED

Shenyang, Liaoning, China
Sun Yat Sen Memorial Hospital
COMPLETED

Guangzhou, Guangdong, China
Suzhou University Affiliated Second Hospital
COMPLETED

Suzhou, Jiangsu, China
The Fifth Medical Center of the General Hospital of the Chinese People's Liberation Army
WITHDRAWN

Beijing, Beijing Municipality, China
The First Affiliated Hospital of Bengbu Medical College
COMPLETED

Bengbu, Anhui, China
The First Affiliated Hospital of Xi'an Jiaotong University
WITHDRAWN

Xian, Shanxi, China
Tonghua Central Hospital
COMPLETED

Tonghua, Jilin, China
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
RECRUITING

Wuhan, Hubei, China
Weifang People's Hospital
COMPLETED

Weifang, Hebei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.